Income Statement
PRELUDE THERAPEUTICS INC
PRLD
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
12.14 | 7.00 | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
12.14 | 7.00 | - | - | - | - |
|
Operating Expenses
|
116.71 | 146.71 | 132.28 | 123.54 | 113.74 | 58.76 |
|
Research & Development
|
94.30 | 118.00 | 103.39 | 92.89 | 86.78 | 48.18 |
|
Selling, General & Administrative
|
22.41 | 28.72 | 28.88 | 30.65 | 26.96 | 10.59 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-104.57 | -139.71 | -132.28 | -123.54 | -113.74 | -58.76 |
|
Non-Operating Income
|
- | - | - | - | - | - |
|
Interest Income
|
- | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
5.07 | 12.54 | 10.45 | 8.10 | 2.04 | 1.83 |
|
Income Before Tax
|
- | - | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-102.86 | -137.94 | -131.11 | -122.22 | -112.82 | -58.22 |
|
Earnings Per Share (Basic)
|
-1.29 | -1.68 | -2.02 | -2.44 | - | - |
|
Diluted EPS
|
-1.29 | -1.68 | -2.02 | -2.44 | - | - |
|
Weighted Average Shares
|
76.96 | 75.81 | 60.36 | 47.37 | - | - |
|
Diluted Weighted Avg Shares
|
76.96 | 75.81 | 60.36 | 47.37 | - | - |
|
Comprehensive Income
|
-99.53 | -127.36 | -119.92 | -116.42 | -112.41 | - |